Albert Bourla (AP Images)

Pfiz­er emerges from pan­dem­ic cru­cible with con­fi­dence to go so­lo in tak­ing mR­NA vac­cines be­yond Covid-19

The pan­dem­ic has changed Pfiz­er.

It’s not just the $15 bil­lion in cash they ex­pect their BioN­Tech-part­nered Covid-19 vac­cine to bring in 2021. Rather, the phar­ma gi­ant is poised for a trans­for­ma­tion from a ma­jor part­ner in mR­NA tech­nol­o­gy to a ma­jor leader with its own de­vel­op­ment and man­u­fac­tur­ing ex­per­tise, with plans to grow the R&D team in Pearl Riv­er, NY by at least 50.

“We are the best po­si­tioned com­pa­ny right now to take it to the next step be­cause of our size and our ex­per­tise,” CEO Al­bert Bourla told the Wall Street Jour­nal in a sit-down in­ter­view.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.